Caregen (CEO Yongji Jeong), a bio company specializing in peptides, announced on the 29th that it participated in the global pharmaceutical, bio, and health functional industry exhibition 'CPHI Korea 2025' held at COEX in Seoul from August 26th to 28th and unveiled its major pipeline and innovative technologies.
CPHI Korea, celebrating its 10th anniversary this year, featured 417 companies from 22 countries around the world, attracting approximately 10,000 buyers. Caregen captivated visitors with a large booth, designed to emphasize its R&D-focused nature and showcased wall graphics and videos visually illustrating clinical data and mechanisms of action.
The exhibition's key product is Korglutide, an oral health functional food that simultaneously targets GLP-1 and IGF-1 receptors. Caregen announced clinical results in July confirming weight loss without muscle loss, and is actively pursuing global market entry by signing supply agreements and completing registration procedures in several countries, including Mexico, India, Ecuador, and Lebanon.
During the exhibition, representatives from numerous global pharmaceutical companies, including those from Turkey, Saudi Arabia, India, China, and Russia, visited the Caregen booth to hold business meetings and discuss partnerships. Discussions also continued with major domestic pharmaceutical companies regarding joint research and development and sales cooperation.
Caregen was recognized for demonstrating the marketability and competitiveness of Korglutide based on its technological prowess and clinical evidence, while also presenting new possibilities within the health functional food industry. Furthermore, active collaboration proposals were made to create synergies with the company's existing product portfolio and distribution channels.
At the official seminar held on the first day of the exhibition, CEO Yongji Jeong presented on the topic, "An Oral GLP-1R & IGF-1R Agonist for Next-Generation Weight Control Without Muscle Loss." The seminar garnered significant attention, selling out early. CEO Jeong continued to hold technical meetings at the booth throughout the exhibition, highlighting the company's R&D-centric identity.
- See more related articles
You must be logged in to post a comment.